RICCI, ANGELA DALIA
RICCI, ANGELA DALIA
Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue
2023 Brandi G.; Deiana C.; Galvani L.; Palloni A.; Ricci A.D.; Rizzo A.; Tavolari S.
The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma
2023 Palloni, Andrea; Bisello, Silvia; Maggio, Ilaria; Massucci, Maria; Galuppi, Andrea; Di Federico, Alessandro; Rizzo, Alessandro; Ricci, Angela Dalia; Siepe, Giambattista; Morganti, Alessio Giuseppe; Brandi, Giovanni; Frega, Giorgio
Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study
2022 Ricci, A. D.; Pusceddu, S.; Panzuto, F.; Gelsomino, F.; Massironi, S.; De Angelis, C. G.; Modica, R.; Ricco, G.; Torchio, M.; Rinzivillo, M.; Prinzi, N.; Rizzi, F.; Lamberti, G.; Campana, D.
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials
2022 Di Federico A.; Rizzo A.; Carloni R.; De Giglio A.; Bruno R.; Ricci D.; Brandi G.
Combining immune checkpoint inhibitors with locoregional therapies in hepatocellular carcinoma
2022 Rizzo A.; Ricci A.D.; Brandi G.
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?
2022 Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, Giorgio Frega, Alessandro Di Federico, Andrea Palloni, Mariacristina Di Marco, Gennaro Gadaleta-Caldarola, Giovanni Brandi
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
2022 Di Federico A.; Mosca M.; Pagani R.; Carloni R.; Frega G.; De Giglio A.; Rizzo A.; Ricci D.; Tavolari S.; Di Marco M.; Palloni A.; Brandi G.
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
2022 Alessandro Di Federico, Mirta Mosca, Rachele Pagani, Riccardo Carloni, Giorgio Frega, Andrea De Giglio, Alessandro Rizzo, Dalia Ricci, Simona Tavolari, Mariacristina Di Marco, Andrea Palloni, Giovanni Brandi.
Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: A meta-analysis
2022 Rizzo A.; Mollica V.; Santoni M.; Ricci A.D.; Gadaleta-Caldarola G.; Montironi R.; Massari F.
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?
2022 Rizzo A.; Dadduzio V.; Ricci A.D.; Massari F.; Di Federico A.; Gadaleta-Caldarola G.; Brandi G.
Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data
2022 Ricci A.D.; Rizzo A.; Mollica V.; Schiavina R.; Fiorentino M.; Brunocilla E.; Ardizzoni A.; Massari F.
Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future
2022 Rizzo A.; Ricci A.D.; Cusmai A.; Acquafredda S.; De Palma G.; Brandi G.; Palmiotti G.
The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy Among Patients with Urothelial Carcinoma: A Meta-Analysis
2022 Rizzo A.; Santoni M.; Mollica V.; Ricci A.D.; Calabro C.; Cusmai A.; Gadaleta-Caldarola G.; Palmiotti G.; Massari F.
Atezolizumab in advanced hepatocellular carcinoma: Good things come to those who wait
2021 Rizzo A.; Ricci A.D.; Brandi G.
Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
2021 Rizzo A.; Ricci A.D.; Brandi G.
Bone targeting agents in patients with metastatic prostate cancer: State of the art
2021 Mollica V.; Rizzo A.; Rosellini M.; Marchetti A.; Ricci A.D.; Cimadamore A.; Scarpelli M.; Bonucci C.; Andrini E.; Errani C.; Santoni M.; Montironi R.; Massari F.
Combination therapy of dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer
2021 Rizzo A.; Ricci A.D.; Brandi G.
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis
2021 Rizzo A.; Mollica V.; Santoni M.; Rosellini M.; Marchetti A.; Ricci A.D.; Grilli G.; Greco A.; Montironi R.; Ardizzoni A.; Massari F.
Detecting and targeting NTRK gene fusions in cholangiocarcinoma: news and perspectives
2021 Rizzo A.; Ricci A.D.; Brandi G.
DNA damage response alterations in gastric cancer: Knocking down a new wall
2021 Ricci A.D.; Rizzo A.; Brandi G.